24 results on '"Bröckelmann, Paul J."'
Search Results
2. Considerations for anti‐PD1‐based first‐line treatment of Hodgkin lymphoma.
3. Low B‐cell content is associated with a CD73‐low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma.
4. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).
5. Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high‐grade B‐cell lymphoma.
6. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
7. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
8. Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine.
9. Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits.
10. S236: HIGH‐BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA.
11. How I treat advanced Hodgkin lymphoma — a global view.
12. Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.
13. P039: HLA expression status and prognostic impact of B‐cell content in patients with early‐stage unfavorable Hodgkin lymphoma.
14. P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma.
15. Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.
16. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
17. P063: Trial in Progress: Individualized Immunotherapy in Early‐Stage Unfavorable Hodgkin Lymphoma ‐ The Investigator‐Initiated Phase II GHSG INDIE Trial.
18. P049: Reduced features of T‐cell activation before and during anti‐PD‐1 treatment in classical Hodgkin lymphoma.
19. P038: HLA expression patterns of Hodgkin‐Reed‐Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma.
20. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
21. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group.
22. Risk stratification and prognostic biomarkers in relapsed Hodgkin lymphoma.
23. Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
24. Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma - combination and personalisation?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.